Bridging the Iron Deficiency Chasm in Heart Failure: The Revolutionary Role of Intravenous Iron in Optimizing Outcomes

Educational Activity

This timely, adaptive, and dynamic educational activity is targeted to physicians, nurses, nurse practitioners, pharmacists, scientists, and other health care professionals who specialize or have an interest in heart failure. Activity attendees will be given the opportunity to interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency (ID) management in the setting of comorbid heart failure (HF). The session will begin with a thorough review of the pathophysiologic underpinnings of ID in HF, specifically the role of hepcidin in hyperinflammatory states (like HF) and the subsequent implications on iron supplementation approaches. The robust prognostic implications and outcomes manifestations of ID in HF, including functional capacity, quality of life, and morbidity and mortality will also be reviewed in detail as a means of providing a foundational knowledge base. In the remainder of the educational session, activity attendees will appraise existing and emerging clinical trial data of IV iron therapies for ID in HF, and then provide a dynamic, case-based opportunity for attendees to apply the information they have learned into real-world clinical scenarios.

 

This educational activity is intended for Physicians, Nurses, Nurse Practitioners, Pharmacists, Scientists, and Health Care Professionals who specialize or have an interest in heart failure.

 

Presented by Creative Educational Concepts, LLC

Supported through an independent educational grant from American Regent.

 

Original recording Date: September 11, 2021

 

 

 

 

 

 

 

 

 

Upon completion of the activity, participants will demonstrate improved competence and ability to:

 

  • Discuss the basic principles of iron metabolism and absorption, and understand the complex pathophysiology of iron deficiency (ID) in heart failure (HF), with a focus on inflammation, hepcidin, and the subsequent impact on the clinical utility of oral vs. IV iron supplementation modalities in HF.
  • Recognize the robust impact of comorbid ID and HF, and describe the practical prognostic manifestations of ID on patient functional capacity, quality of life, and morbidity and mortality outcomes.
  • Review the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices for ID, and differentiate the practical distinctions between functional and absolute iron deficiency.
  • Appraise existing, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal trials that have influenced current practice and consensus guidelines for ID management in HF (ESC and ACC/AHA/HFSA).
  • Distinguish among the FDA-approved IV iron agents, including recent dosing recommendations, indications, and the pharmacologic nuances that yield unique clinical utility and impact.
  • Using a real-world, case-based format, analyze the evolving placement of IV iron products in the HF treatment calculus, with emphasis on the evidence-driven translation of recent trial data into clinical practice.

Accreditation Statement

 

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

The Heart Failure Society of America designates this enduring educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Learners should claim only the credit commensurate with the extent of their participation in the activity.
 

LO_Icon

Credits Available

CME

Powered by Oasis.